Koronis Pharmaceuticals
Seattle
About Koronis Pharmaceuticals
Koronis Pharmaceuticals develops antiviral therapeutics based on a viral decay acceleration mechanism. It is a privately held biotechnology company developing antiviral therapeutics based on a novel mechanism, Viral Decay Acceleration™ (VDA). The Company's lead product candidate is KP-1461 for the treatment of human immunodeficiency virus (HIV). The Company also has products in development for the treatment of hepatitis C and RSV. It was founded in 1998 and is based in Seattle, Washington.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $21.1M
- Last round: Debt Financing (Sep 2015)
- Website: koronispharma.com
- Phone: +1 206-682-1181
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/koronis-pharmaceuticals-3151413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.